Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: Predictive value for a complicated course?

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 4, 2004, Pages 311-316

  Niessner, Alexander ^a   Hornykewycz, Stephan ^b   Graf, Senta ^a   Nikfardjam, Mariam ^a   Speidl, Walter S ^a   Probst, Peter ^a   Zorn, Gerlinde ^a   Maurer, Gerald ^a   Wojta, Johann ^a   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticardiolipin antibodies; Coronary balloon angioplasty; Lipoprotein (a); Plasminogen activator inhibitor type 1; Restenosis; Tissue plasminogen activator; Von Willebrand factor

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; PARAMETER; PATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECURRENT ABORTION; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, ANTICARDIOLIPIN; BIOLOGICAL MARKERS; CORONARY RESTENOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK; THROMBOPHILIA;

EID: 2942564573     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200406000-00004     Document Type: Article

References (40)

1. Taubes G. Cardiovascular disease. Does inflammation cut to the heart of the matter? Science 2002; 236:242-245.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
4. Weyand CM, Goronzy JJ, Liuzzo G, Kopecky SL, Holmes DR, Jr., Frye RL. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001; 76:1011-1020.
5. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
6. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-763.
7. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997; 337:154-160.
8. Roubey RA. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7(suppl 2):S114-S119.
9. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15:237-240.
10. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
11. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001; 32:1701-1706.
12. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102:2576-2581.
13. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:3159-3163.
14. Bili A, Moss AJ, Francis CW, Zareba W, Watelet LF, Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000; 102:1258-1263.
15. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992; 339:451-453.
16. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J 1993; 69:391-394.
17. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20:204-209.
18. Chiarugi L, Prisco D, Antonucci E, Capanni M, Fedi S, Liotta AA, et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 2001; 154:129-135.
19. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B, et al. Antioxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999; 68:263-266.
20. Ludia C, Domenico P, Monia C, Emilia A, Sandra F, Agatina AL, et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity 1998; 27:141-148.
21. Blum A, Vardinon N, Kaplan G, Laniado S, Yust I, Burk M, et al. Autoimmune and inflammatory responses may have an additive effect in postpercutaneous transluminal coronary angioplasty restenosis. Am J Cardiol 1998; 81:339-341.
22. Eber B, Schumacher M, Auer-Grumbach P, Toplak H, Klein W. Increased IgM-anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69:1255-1258.
23. Tsakiris DA, Marbet GA, Burkart F, Duckert F. Anticardiolipin antibodies and coronary heart disease. Eur Heart J 1992; 13:1645-1648.
24. Yutani C, Imakita M, Ishibashi-Ueda H, Tsukamoto Y, Nishida N, Ikeda Y. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol Int 1999; 49:273-290.
25. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682-698.
26. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301:61-68.
27. Kalunian KC, Peter JB, Middlekauff HR, Sayre J, Ando DG, Mangotich M, et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85:602-608.
28. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68:215-222.
29. Harris EN. Solid-phase anti-cardiolipin test revisited. Am J Med 1988; 85:599-601.
30. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74:1-9.
31. Verheijen JH, Chang GT, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51:392-395.
32. Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator. J Lab Clin Med 1985; 105:718-724.
33. Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41:527-535.
34. Horkko S, Olee T, Mo L, Branch DW, Woods VL, Jr., Palinski W, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001; 103:941-946.
35. Yamazaki M, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994; 71:424-427.
36. Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M. Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol 1996; 14:593-599.
37. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98:815-825.
38. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001; 108:1097-1104.
39. Wainwright CL, Miller AM, Wadsworth RM. Inflammation as a key event in the development of neointima following vascular balloon injury. Clin Exp Pharmacol Physiol 2001; 28:891-895.
40. Zairis MN, Papadaki OA, Psarogianni PK, Thoma MA, Andrikopoulos GK, Batika PC, et al. Serologic markers of persistent Chlamydia pneumonia infection and long-term prognosis after successful coronary stenting. Am Heart J 2003; 146:1082-1089.